Results 71 to 80 of about 11,489 (193)

mRNA Vaccine Against Mpox: A Promising Healthcare Strategy

Animal Research and One Health, Volume 3, Issue 2, Page 177-180, May 2025.
Mohammad Shah Alam, Md. Arman Sharif, Md. Aminul Islam, M. Nazmul Hoque   +3 more
wiley   +1 more source

Perfusion Process Intensification for Lentivirus Production Using a Novel Scale‐Down Model

Biotechnology and Bioengineering, Volume 122, Issue 2, Page 344-360, February 2025.
A scale‐down model of the acoustic wave‐mediated cell retention technology was used in combination with a mini‐bioreactor system to develop an intensified perfusion process for the production of recombinant lentiviruses. The enhanced process was scaled up to bench‐top bioreactor scale, resulting in a threefold increase in functional vector yield ...
Maximilian Klimpel, Beatrice Pflüger‐Müller, Marta Arrizabalaga Cascallana, Sarah Schwingal, Nikki Indresh Lal, Thomas Noll, Vicky Pirzas, Holger Laux   +7 more
wiley   +1 more source

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review [PDF]

, 2015
Background The existing Bacillus Calmette–Guérin (BCG) vaccination provides partial protection against tuberculosis (TB). The modified vaccinia ankara virus-expressing antigen 85A (MVA85A) aims to boost BCG immunity.
Garner, Paul, Kashangura, Rufaro, Sena, Emily, Young, Taryn   +3 more
core   +1 more source

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. [PDF]

, 2020
On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO).
Du, Lanying, Jiang, Shibo, Ojcius, David M, Pan, Chungen, Yu, Fei   +4 more
core   +1 more source

Modified Vaccinia Virus Ankara

, 2017
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and ...
Gerd Sutter, Asisa Volz
openaire   +2 more sources

Atypical mucocutaneous manifestations of MPOX: A systematic review

The Journal of Dermatology, Volume 52, Issue 2, Page 228-238, February 2025.
Abstract MPOX is an orthopoxvirus whose infection has been declared a Public Health Emergency of International Concern in 2022 and 2024. It proved to be a virus with markedly heterogeneous and varied clinical presentation. We performed a systematic PubMed review of articles reporting cases of different clinical manifestations of MPOX until October 2024.
Andrés Grau‐Echevarría, Daniel Blaya‐Imbernón, Malena Finello, Elena Pérez Zafrilla, Ángel González García, Rodrigo Peñuelas Leal, Carolina Labrandero‐Hoyos, Jorge Magdaleno‐Tapial, Esther Díez‐Recio, Pablo Hernández‐Bel   +9 more
wiley   +1 more source

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR, Elena Stylianou, Helen McShane, Matthew J. Paul, Rajko Reljic, Resende Co T, Rodriguez A, Uranga S, Wong EA   +8 more
core   +1 more source

Tissue‐resident memory T cells in diseases and therapeutic strategies

MedComm, Volume 6, Issue 1, January 2025.
Tissue‐resident memory T (TRM) cells are crucial components of the immune system and play vital roles in antiviral, antibacterial, and antitumor immunity, as well as chronic inflammation conditions and graft‐versus‐host diseases. Understanding the intricate regulation of TRM cells is crucial for developing targeted therapeutic strategies, such as ...
Daoyuan Xie, Guanting Lu, Gang Mai, Qiuyan Guo, Guofeng Xu   +4 more
wiley   +1 more source

Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model [PDF]

, 2008
BACKGROUND: Efficient vaccines against hepatitis C virus (HCV) infection are urgently needed. Vaccine development has been hampered by the lack of suitable small animal models to reliably test the protective capacity of immmunization. METHODS: We used
Adler, Adler, Arribillaga, Battegay, Bergqvist, Bruna-Romero, Cerny, Diepolder, Diepolder, Eisen-Vandervelde, El-Gogo, Fischer, Flano, Flano, Folgori, Frelin, Geissler, Gerlach, Gonzalez-Aseguinolaza, Grakoui, Gruener, Houghton, Inchauspe, Kato, Kittlesen, Large, Major, Marques, McLauchlan, Messerle, Nascimbeni, Nash, Rollier, Schirren, Shirai, Shoukry, Staib, Staib, Staib, Staib, Stevenson, Stewart, Sunil-Chandra, Takaki, Thimme, Ulsenheimer, Usherwood, Virgin, Virgin, Weck, Willer, Yao   +51 more
core   +1 more source

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model

PLoS ONE, 2010
Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether an MVA which does not encode any antigen (Ag) could be exploited as adjuvant per se.We showed that dendritic cells ...
Nörder, M., Becker, P.D., Drexler, I., Link, C., Erfle, V., Guzman, C.A.   +5 more
openaire   +7 more sources